Jason N. Butler - JMP Securities LLC, Research Division

I guess the first one on the enrollment on the Type 1 trial, can you talk about what your assumptions were for the duration of the titration period and whether you're actually seeing that in the early experience in the trial?

Peter C. Richardson - Chief Scientific Officer and Corporate Vice President

Yes. They're not really assumptions, they're vertical defined and we've agreed with agency in terms of what the titration period would look like. So you're looking at a 12-week titration.

Alfred E. Mann - Founder, Chairman and Chief Executive Officer

We actually started with 8 weeks and the agency came back and said we'd more comfortable with 10 weeks. And we decided to increase it to 12 because with the 12 weeks and 12 weeks of observation, we can meet the European standards.

http://seekingalpha.com/article/305499-mannkind-s-ceo-discusses-q3-2011-results-earnings-call-transcript?find=titration&all=false